|
download
PDF
|
Changes in Management of Head and Neck Malignancies during the COVID-19 Pandemic
Abstract
Objective. Despite multiple studies from high-income countries, reports from low- and middle-income countries on the impact of COVID-19 on head and neck cancer care remain sparse. This study aimed to assess the effects of the COVID-19 pandemic on head and neck cancer patients at a tertiary reference centre in Bosnia and Herzegovina.
Methods. We included 228 patients with malignant head and neck tumours evaluated and treated between January 1, 2019, and December 31, 2021. Patient demographics, histological characteristics, and treatment modalities were retrospectively obtained and compared between the pre-pandemic period (pre-COVID-19 group) and the period after the implementation of COVID-19 restrictive measures (COVID-19 group).
Results. Patients were significantly older during the COVID-19 pandemic. In particular, 63 patients (44.7%) were under 65 and 78 (55.3%) were 65 or older, while in the pre- COVID-19 period, 53 patients (60.9%) were under 65 and 34 (39.1%) were 65 or older (p = 0.017). The pre-COVID-19 and COVID-19 groups did not significantly differ regarding other patient- and tumour characteristics, or primary treatment modalities.
Conclusions. During the COVID-19 pandemic, significantly fewer patients were under 65 at the time of initial work-up, potentially reflecting the more enhanced disease-related anxiety of the younger population. Future studies are warranted to address this population’s specific educational and psychological needs to ensure appropriate cancer care.
Introduction
Since the onset of the COVID-19 pandemic in 2020, high mortality rates relative to other respiratory infectious diseases, coupled with the emergence of new variants, have continued to strain healthcare providers worldwide 1. Furthermore, recent studies have demonstrated that pandemic-related restrictions have severely compromised the timely and comprehensive provision of cancer care 2,3. Notably, nations with well-resourced healthcare systems, including sufficient hospital capacity, medical personnel, and essential medical equipment, generally managed the pandemic better than countries with limited resources 4. However, the majority of current literature investigating the impact of COVID-19 on cancer care originates from high-income countries and lacks the perspective of low- and middle-income countries 5.
The first case of COVID-19 in Bosnia and Herzegovina (B&H) was reported on March 5, 2020 6. By May 16, 2020, the number of confirmed COVID-19 cases had surged to 2,236, prompting the government to implement widespread restrictive measures, including movement restrictions, closure of public institutions, cafes, bars, and restaurants, as well as restrictions in public spaces and airports 6. By March 31, 2022, B&H had documented 249,495 COVID-19 cases and 8,845 COVID-19-associated deaths 7. Nearly a year later, a combination of low vaccine acceptance rates, limited health care resources and fatigued healthcare workers, created a challenging environment for B&H to effectively manage the ongoing COVID-19 pandemic 8-10. The combination of these factors, along with patient-centred variables such as fear and uncertainty surrounding COVID-19, led to patients presenting with more advanced stages of head and neck cancer during the pandemic 11,12. Certainly, identifying disparities to inform national healthcare policies is crucial to improve the management of cancer care during the pandemic, especially in light of future pandemic developments.
The data on the impact of the COVID-19 pandemic on head and neck cancer care in low- or middle-income countries remain sparse. Therefore, the aim of this study was to assess the impact of the pandemic on patients who presented with head and neck malignancies at a tertiary referral centre in B&H. In particular, we compared patient characteristics, including demographics, tumour characteristics and treatment modalities, between patients who presented before and during the pandemic.
Methods
Study population and study design
This retrospective cohort study included all patients with malignant tumours of the head and neck region who received treatment at the Department of Otorhinolaryngology at the University Clinical Center Tuzla, B&H, from January 1, 2019, to December 31, 2021. Patients with incomplete medical records were excluded from the analysis. The study period was divided into two periods: the pre-COVID-19 period, spanning from January 1, 2019, to March 15, 2020, and the COVID-19 period, spanning from March 16, 2020, to December 31, 2021, following the implementation of the first governmental restrictions in B&H. Patient demographics, tumour characteristics and treatment modalities were compared between the two time periods. Tumour characteristics included information on the primary site, histotype, TNM-classification, clinical staging, grading, and subsite. Staging was performed using the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual 13. The therapeutic modalities were primary surgery with or without postoperative radiotherapy (RT), primary RT, chemotherapy (CHT), radio-chemotherapy (RCHT), and palliative therapy. Due to the recency of the COVID-19 pandemic, the follow-up periods were different between the two cohorts. Therefore, survival analyses were omitted.
Statistical analysis
All categorical variables are presented as numbers and percentages. We used Pearson’s chi-squared test to examine differences between groups. For groups with less than 5 patients, Fisher’s exact test was used. A p value of ≤ 0.05 was considered statistically significant. Statistical analyses were performed using STATA (Version 14, StataCorp LLC, College Station, Texas USA).
Results
A total of 228 patients with head and neck malignancies were treated during the study period. In particular, the pre-COVID-19 group included 87 patients (38.2%), while 141 patients (61.8%) received treatment during the COVID-19 pandemic.
Patient demographics
Our cohort comprised 116 patients (50.9%) under the age of 65 and 112 (49.1%) over 65. In terms of gender, 161 (70.6%) patients were males and 67 (29.4%) females (Tab. I). Interestingly, during the pre-COVID-19 period, significantly fewer patients aged under 65 at the time of the initial work-up (p = 0.017). In particular, 53 patients (60.9%) were under the age of 65 in the pre-COVID-19 group, while during the COVID-19 period, 63 patients (44.7%) were under 65. There were no significant differences in gender distribution between the two time periods (p = 0.282).
Tumour characteristics
Table II summarises the tumour characteristics before and during the COVID-19 pandemic. Histopathological analysis revealed that 161 patients (70.6%) presented with squamous cell carcinoma, while four (1.8%) and two (0.9%) presented with myoepithelial and adenoid cystic carcinoma, respectively. Moreover, one patient (1.8%) presented with invasive ductal carcinoma of the salivary gland. Regarding thyroid cancers, 37 patients (16.2%) presented with papillary thyroid carcinoma, six (2.6%) with follicular thyroid carcinoma, and two (0.9%) with medullary thyroid carcinoma. Additionally, seven (3.1%) patients presented with basal cell carcinoma, while three (1.3%) were diagnosed with a malignant melanoma of the skin. We did not observe a significant difference between the pre-COVID-19 and the COVID-19 periods regarding the distribution of histopathological diagnoses (p = 0.712).
In 155 patients (68%), the primary cancer site was the head and neck mucosa, in 47 (20.6%) the thyroid gland and in 26 (11.4%) the skin. Specifically, within the head and neck region, 103 (45.2%), 47 (20.6%), 26 (11.4%), six (2.6%), one (0.4%), five (2.2%), and five (2.2%) patients had carcinomas located in the larynx, thyroid gland, oropharynx, hypopharynx, nasopharynx, sinonasal, and salivary glands, respectively. Nine patients (3.9%) presented with cancer of unknown primary (CUP). No significant differences were observed when comparing the distribution of primary tumour sites and head and neck cancer subsites before and during the pandemic (p = 0.886 and p = 0.565, respectively).
Moreover, we did not observe a significant difference in the distribution of the T (p = 0.566) or N category (p = 0.067). Only one patient (0.7%), treated during the pandemic, had distant metastases at the initial check-up.
Lastly, the groups showed no significant differences in tumour stage (p = 0.802) or grade (p = 0.609).
Impact of the COVID-19 pandemic on treatment modalities
Throughout the entire study period, 187 patients (81.6%) underwent a primary surgical resection. Eight patients (3.5%) were treated with primary definitive RT and four patients (1.8%) received RCHT. Furthermore, one patient (0.4%) received CHT. Overall, 17 patients (7.5%) were admitted to palliative best-supportive care, and the primary treatment modality was missing in 12 patients (5.3%). Notably, no significant differences in the distribution of treatment modalities between the pre- and COVID-19 period was observed (p = 0.975; Table III).
Discussion
The present study provides first insights into the impact of the COVID-19 pandemic on demographics, tumour characteristics, and treatment modalities of head and neck cancer patients in a tertiary academic centre in B&H. As the main finding of our study, patients were significantly older at initial presentation after the introduction of COVID-19 restrictions in March 2020.
Other than patient age, we found no differences in tumour characteristics, primary sites, and clinical staging between the two time periods. In particular, tumours were not more advanced during the pandemic. These results contradict most studies about the impact of COVID-19 on head and neck cancer care. The COVIDSurg collaborative multicentre study 14 and several other studies revealed a trend toward larger tumours, higher stages and aggravated nodal status during the COVID-19 pandemic 12,15. Similar observations were noted for other cancer entities 2. However, the impact of COVID-19 on head and neck cancer care differed among countries. For example, studies from France showed no change in tumour stage during the pandemic 16. Even within high-income countries, contradictory results have been observed. While a study from California by Solis et al. 12 noted more extensive tumours and higher T categories, a study from Tennessee by Stevens et al. 17 reported no such differences. Although the lack of generalisability of single-centre studies is considered a limitation, we believe that studies from different areas are essential to reflect the different needs of the specific local population.
As aforementioned, the cohort was significantly older during the pandemic, compared to the pre-COVID-19 group, which might have been caused due to fear of transmission by the younger population. Undoubtedly, the COVID-19 outbreak had an unprecedented effect on healthcare providers worldwide. Especially in the early phase, the COVID-19 pandemic was associated with uncertainties regarding transmission, severity of the disease, and mortality rates. Recent studies proved that the fear of COVID-19 infection and transmission caused patients to cancel elective surgeries to avoid hospital admissions 18. Furthermore, in patients with oncologic diseases, gaps in oncologic care and isolation during the COVID-19 pandemic severely aggravated those fears 11,19. At the beginning of the pandemic, it was suspected that due to poor survival rates, higher numbers of physical and psychological comorbidities, and social isolation, older people would be significantly more affected by COVID-19-related fear 20. However, the current literature shows a trend towards lower levels of COVID-19 related anxiety and depression in older people than in younger people. A study from Brazil showed, despite higher chances of severe disease and higher mortality, that people over 60 had a significant decrease in fear of infection or transmission 19. This age-related protective effect of COVID-19-related fear was also shown in studies from Qatar, Spain, and China 20-22. A nationwide multicentre study by Wang et al., involving 19,372 individuals, revealed that those aged 35-49 had more severe depressive and anxiety symptoms compared to other age groups, especially those aged 65 and above 20. We therefore suggest that higher fear in younger people might have led to fewer hospital presentations during the COVID-19 pandemic. Nevertheless, cultural differences regarding beliefs and values around health and illness, social norms like mask-wearing and social distancing, trust in authorities, communal responsibility, and obedience to governmental restrictions, might significantly impact the individual country’s response to the COVID-19 pandemic. Understanding these differences is important for developing targeted, effective interventions adapted to the specific patient population to ultimately improve the management of head and neck cancer patients.
Several strategies have been proposed to address the age-related fear of COVID-19 in cancer care. First, telemedicine approaches can ensure early detection and regular follow-up of head and neck cancer patients while being accepted by a broad range of patient populations 23. This approach allows individuals with high levels of COVID-19 anxiety to stay away from hospitals. Furthermore, implementing contingency plans can instill a sense of security and ensure the continuity of patient care during a pandemic 24.
Finally, this was the first study on the effects of the pandemic on the treatment of head and neck cancer patients in B&H. Interestingly, B&H was the country with the fourth highest mortality due to COVID-19 globally in January 2021 8. The country faced political and bureaucratic obstacles that hindered its ability to effectively response to the pandemic 8. Additionally, the relatively low level of public awareness and compliance with public health guidelines, such as wearing masks and social distancing, may have contributed to the rapid spread of the virus within communities 8. Accordingly, the present study’s results are reassuring and show that our reference center was able to maintain a stable level of head and neck cancer patient care during the pandemic, despite several pandemic-related restraints.
Several limitations counter the findings of the present study. First, the retrospective design is associated with an inherent bias regarding data availability due to the use of historical data, which did not allow us to retrieve time intervals between diagnosis and treatment initiation. Moreover, it should be further elucidated if the pandemic hindered timely therapy starting after a diagnosis of cancer. Additionally, the generalisability of our results may be limited since our study is a single-institution experience. Future studies should implement a multicentric assessment of hospitals in B&H or from adjacent regions to create a more comprehensive picture and point out the specific needs of this patient population.
Conclusions
This study provides insights into the effects of the COVID-19 pandemic on managing head and neck cancer patients in the middle-income country of B&H. The pandemic cohort presented with a significantly older population, emphasising the potential impact of disease-related anxiety on younger individuals, which may result in delayed diagnosis and treatment of cancer. Future efforts should prioritise this population’s specific informational and psychological needs to ensure timely and appropriate cancer care, especially in the event of future pandemics. Furthermore, this study can serve as a foundation for future research on the impact of COVID-19 on cancer patients within different healthcare systems.
Conflict of interest statement
The authors declare no conflict of interest.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author contributions
AL: design, acquisition of data, analysis, and writing of the manuscript; FB: design, analysis, and supervision; DTL: design, acquisition of data, analysis, and critical revision of the manuscript; MH: design, analysis, and critical revision of the manuscript; AS: design, acquisition of data, analysis, and critical revision of the manuscript; AI: acquisition of data, and critical revision of the manuscript; TT: analysis, and critical revision of the manuscript; SU: acquisition of data, and critical revision of the manuscript; AH: acquisition of data, and critical revision of the manuscript; FFB: design, acquisition of data, analysis, writing of the manuscript, and supervision.
Ethical consideration
The current study was approved by the Ethics Committee of the University Clinical Center Tuzla (Nr. 02-09/2-29/22) and was conducted following the principles of the Declaration of Helsinki. Patient consent was waived due to the retrospective nature of the study.
Figures and tables
| Variables/categories | Total (n = 228) | pre-COVID-19 (n = 87) | COVID-19 (n = 141) | Difference between pre-COVID-19 and COVID-19 | p value | ||
|---|---|---|---|---|---|---|---|
| Age | |||||||
| < 65 | 116 | 53 | (60.9%) | 63 | (44.7%) | -16.2% | |
| ≥ 65 | 112 | 34 | (39.1%) | 78 | (55.3%) | 16.2% | 0.017 |
| Gender | |||||||
| Male | 161 | 65 | (74.7%) | 96 | (68.1%) | -6.6% | |
| Female | 67 | 22 | (25.3%) | 45 | (31.9%) | 6.6% | 0.286 |
| Variables/categories | Total (n = 228) | pre-COVID-19 (n = 87) | COVID-19 (n = 141) | Difference between pre-COVID-19 and COVID-19 | p value | ||
|---|---|---|---|---|---|---|---|
| Histology | |||||||
| Squamous cell | 161 | 60 | (69%) | 101 | (71.6%) | 2.7% | |
| Papillary thyroid | 37 | 16 | (18.4%) | 21 | (14.9%) | -3.5% | |
| Follicular thyroid | 6 | 3 | (3.4%) | 3 | (2.1%) | -1.3% | |
| Medullary thyroid | 2 | 1 | (1.1%) | 1 | (0.7%) | -0.4% | |
| Basal cell | 7 | 1 | (1.1%) | 6 | (4.3%) | 3.1% | |
| Malignant melanoma | 3 | 2 | (2.3%) | 1 | (0.7%) | -1.6% | |
| Myoepithelial | 4 | 1 | (1.1%) | 3 | (2.1%) | 1% | |
| Adenoid cystic | 2 | 0 | (0%) | 2 | (1.4%) | 1.4% | |
| Invasive ductal | 1 | 0 | (0%) | 1 | (0.7%) | 0.7% | |
| Other§ | 5 | 3 | (3.4%) | 2 | (1.4%) | -2% | 0.712 |
| Primary site | |||||||
| Head and neck | 155 | 59 | (67.8%) | 96 | (68.1%) | 0.3% | |
| Thyroid | 47 | 19 | (21.8%) | 28 | (19.9%) | -2% | |
| Skin | 26 | 9 | (10.3%) | 17 | (12.1%) | 1.7% | 0.886 |
| Head and neck subsite | |||||||
| Larynx | 103 | 42 | (71.2%) | 61 | (63.5%) | -7.6% | |
| Oropharynx | 26 | 11 | (18.6%) | 15 | (15.6%) | -3% | |
| Hypopharynx | 6 | 1 | (1.7%) | 5 | (5.2%) | 3.5% | |
| Nasopharynx | 1 | 1 | (1.7%) | 0 | (0%) | -1.7% | |
| Sinonasal | 5 | 1 | (1.7%) | 4 | (4.2%) | 2.5% | |
| Salivary gland | 5 | 1 | (1.7%) | 4 | (4.2%) | 2.5% | |
| CUP | 9 | 2 | (3.4%) | 7 | (7.3%) | 3.9% | 0.565 |
| T category | |||||||
| Tis | 11 | 3 | (3.4%) | 8 | (5.7%) | 2.2% | |
| T1 | 69 | 23 | (26.4%) | 46 | (32.6%) | 6.2% | |
| T2 | 65 | 24 | (27.6%) | 41 | (29.1%) | 1.5% | |
| T3 | 57 | 24 | (27.6%) | 33 | (23.4%) | -4.2% | |
| T4 | 18 | 10 | (11.5%) | 8 | (5.7%) | -5.8% | |
| Tx | 8 | 3 | (3.4%) | 5 | (3.5%) | 0.1% | 0.566 |
| N category | |||||||
| N0 | 129 | 43 | (49.4%) | 86 | (61%) | 11.6% | |
| N1 | 27 | 17 | (19.5%) | 10 | (7.1%) | -12.4% | |
| N2 | 33 | 11 | (12.6%) | 22 | (15.6%) | 3% | |
| N3 | 15 | 6 | (6.9%) | 9 | (6.4%) | -0.5% | |
| Nx | 24 | 10 | (11.5%) | 14 | (9.9%) | -1.6% | 0.067 |
| M category | |||||||
| M0 | 227 | 87 | (100%) | 140 | (99.3%) | -0.7% | |
| M1 | 1 | 0 | (0%) | 1 | (0.7%) | 0.7% | 1.000 |
| Stage | |||||||
| 0 | 11 | 3 | (3.4%) | 8 | (5.7%) | 2.2% | |
| I | 76 | 27 | (31%) | 49 | (34.8%) | 3.7% | |
| II | 50 | 20 | (23%) | 30 | (21.3%) | -1.7% | |
| III | 35 | 16 | (18.4%) | 19 | (13.5%) | -4.9% | |
| IV | 51 | 19 | (21.8%) | 32 | (22.7%) | 0.9% | 0.806 |
| Unknown | 5 | 2 | (2.3%) | 3 | (2.1%) | -0.2% | |
| Grading | |||||||
| G1 | 10 | 5 | (5.7%) | 5 | (3.5%) | -2.2% | |
| G2 | 84 | 29 | (33.3%) | 55 | (39%) | 5.7% | |
| G3 | 44 | 15 | (17.2%) | 29 | (20.6%) | 3.3% | 0.609 |
| Unknown | 88 | 36 | (41.4%) | 52 | (36.9%) | -4.5% | |
| CUP: cancer of unknown primary; §: sarcoma (n = 4); chordoma (n = 1). | |||||||
| Variables/categories | Total (n = 228) | pre-COVID-19 (n = 87) | COVID-19 (n = 141) | Difference between pre-COVID-19 and COVID-19 | p value | ||
|---|---|---|---|---|---|---|---|
| Primary treatment | |||||||
| Primary surgery | 186 | 71 | (81.6%) | 115 | (81.6%) | 0% | |
| RT | 8 | 4 | (4.6%) | 4 | (2.8%) | -1.8% | |
| CHT | 1 | 0 | (0%) | 1 | (0.7%) | 0.7% | |
| RCHT | 4 | 1 | (1.1%) | 3 | (2.1%) | 1% | |
| Palliative care | 17 | 6 | (6.9%) | 11 | (7.8%) | 0.9% | |
| Unknown | 12 | 5 | (5.7%) | 7 | (5%) | -0.8% | 0.975 |
| RT: radiotherapy; CHT: chemotherapy; RCHT: radio-chemotherapy. | |||||||
References
- WHO. Statement on the fourteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic.Publisher Full Text
- Rottoli M, Gori A, Pellino G. Colorectal cancer stage at diagnosis before vs during the COVID-19 pandemic in Italy. JAMA Netw Open. 2022; 5:E2243119. DOI
- Ballal Y, Gete M, Su J. The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis. Oral Oncol. 2023;106332. DOI
- Bong CL, Brasher C, Chikumba E. The COVID-19 pandemic: effects on low- and middle-income countries. Anesth Analg. 2020; 131:86-92. DOI
- Djoutsop OM, Mbougo JV, Kanmounye US. Global head and neck surgery research during the COVID pandemic: a bibliometric analysis. Ann Med Surg (Lond). 2021; 68:102555. DOI
- Arapović J, Skočibušić S. The first two months of the COVID-19 pandemic in Bosnia and Herzegovina: single-center experience. Bosn J Basic Med Sci. 2020; 20:396-400. DOI
- Musa S, Blažević M, Kavazović A. COVID-19 in the Federation of Bosnia and Herzegovina: strengthening the public health surveillance using a web-based system to inform public health response, March 2020 - March 2022. Biomol Biomed. 2023; 26:718-725. DOI
- Fojnica A, Osmanovic A, Đuzic N. COVID-19 vaccine acceptance and rejection in an adult population in Bosnia and Herzegovina. PLoS One. 2022; 17:E0264754. DOI
- Marijanović I, Kraljević M, Buhovac T. Use of the Depression, Anxiety and Stress Scale (DASS-21) questionnaire to assess levels of depression, anxiety, and stress in healthcare and administrative staff in 5 oncology institutions in Bosnia and Herzegovina during the 2020 COVID-19 pandemic. Med Sci Monit. 2021; 27:E930812. DOI
- Lein A, Liu DT, Haas M. Impact of the COVID-19 pandemic on management of surgically treated laryngeal squamous cell carcinoma. Biomol Biomed. 2024; 24:188-195. DOI
- Bandinelli L, Ornell F, von Diemen L. The sum of fears in cancer patients inside the context of the COVID-19. Front Psychiatry. 2021; 12:557834. DOI
- Solis RN, Mehrzad M, Faiq S. The impact of COVID-19 on head and neck cancer treatment: before and during the pandemic. OTO Open. 2021; 5:2473974x211068075. DOI
- Zanoni DK, Patel SG, Shah JP. Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep. 2019; 21:52. DOI
- COVID Surg-Collaborative. Head and neck cancer surgery during the COVID-19 pandemic: an international, multicenter, observational cohort study. Cancer. 2021; 127:2476-2488. DOI
- Kim SH, Min E, Hwang YM. Impact of COVID-19 pandemic on thyroid surgery in a university hospital in South Korea. Cancers (Basel). 2022; 14:4338. DOI
- Laccourreye O, Mirghani H, Evrard D. Impact of the first month of COVID-19 lockdown on oncologic surgical activity in the Ile de France region university hospital otorhinolaryngology departments. Eur Ann Otorhinolaryngol Head Neck Dis. 2020; 137:273-276. DOI
- Stevens MN, Patro A, Rahman B. Impact of COVID-19 on presentation, staging, and treatment of head and neck mucosal squamous cell carcinoma. Am J Otolaryngol. 2022; 43:103263. DOI
- Agrawal S, Dróżdż M, Makuch S. The assessment of fear of COVID-19 among the elderly population: a cross-sectional study. J Clin Med. 2021; 10:5537. DOI
- Alhalal E, Alkhair Z, Alghazal F. Fear of contamination among older adults in the post-COVID-19 era. Geriatr Nurs. 2022; 48:1-7. DOI
- Wang C, Pan R, Wan X. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020; 17:1729. DOI
- Ouanes S, Kumar R, Doleh ESI. Mental health, resilience, and religiosity in the elderly under COVID-19 quarantine in Qatar. Arch Gerontol Geriatr. 2021; 96:104457. DOI
- Justo-Alonso A, García-Dantas A, González-Vázquez AI. How did different generations cope with the COVID-19 pandemic? Early stages of the pandemic in Spain. Psicothema. 2020; 32:490-500. DOI
- Tam S, Wu VF, Williams AM. Disparities in the uptake of telemedicine during the COVID-19 surge in a multidisciplinary head and neck cancer population by patient demographic characteristics and socioeconomic status. JAMA Otolaryngol Head Neck Surg. 2021; 147:209-211. DOI
- Givi B, Schiff BA, Chinn SB. Safety recommendations for evaluation and surgery of the head and neck during the COVID-19 pandemic. JAMA Otolaryngol Head Neck Surg. 2020; 146:579-584. DOI
Affiliations
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright
© Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale , 2024
- Abstract viewed - 534 times
- PDF downloaded - 207 times